DTx East Agenda

DTx East is going virtual. Working with industry leaders, we are providing even more high-quality learning and networking opportunities than usual, but this time, through a truly interactive virtual experience.

Through a more personalized and flexible experience, attendees will be able to participate in live polls, actively or passively take part in roundtables, instantly message fellow attendees, join a variety of networking sessions and much more. Oh, and not to mention the rockstar speaker faculty and crucial topics on the agenda.

With the recent changes in healthcare, it is now more crucial than ever to accelerate digital therapeutics into the hands of patients with unmet medical needs.

Download the Agenda

Conference Day 1: Workshops

The digital therapeutics industry is being tried and tested both in the clinic and real world, reporting some outstanding results for patients. However, there are only a few examples of commercial success demonstrated in space. This workshop will deep-dive into the various commercial opportunities, how to approach them and how to identify the best partner for you.

  • Workshop 1 - The Business of Digital Therapeutics
  • Workshop 2 - The Regulatory Masterclass
Workshop 1 - The Business of Digital Therapeutics

Workshop Leaders:

Chris Wasden, Head of HappifyDTx, Happify Health

Mette Dyhrberg, Founder & Chief Executive Officer, Mymee

Pablo Pantaleoni, Vice President & General Manager of Health, Headspace

9:00am

Presentation: An Inside Look at the Business of Digital Therapeutics

  • A brief overview of the various business models adopted by digital therapeutic companies
  • Where can we see commercial success in the industry so far?
  • When should digital therapeutics companies begin searching for reimbursement opportunities and who can offer them these opportunities?
9:30am

Breakout Discussions

Splitting into smaller groups, you will discuss the intricacies of the business of digital therapeutics and hear views on how best to successfully run a business in the DTx industry. Make notes on the virtual platform for all members of the group to contribute to, on the following:

  • What are the current business models being used within the industry and which are demonstrating the most success?
  • How do some business models favour certain types of digital therapeutic over others?
  • How can we learn from others successes and failures to ensure we are moving forward as an industry?
  • Can pharma help provide effective and recurring reimbursement for digital therapeutics?
  • What can we learn from other areas of digital health?
10:30am

Networking Break

11:00am

Feedback Session

Representative(s) from each group will be invited onto the virtual “stage” to share the main points from their discussion to the whole group. Additional questions from moderators and other group members will be raised, via interactive polls, during this collaborative discussion. 

Summary thoughts will then be shared by the moderator(s) and all participants will leave with the below:

Leave this workshop with:
  • A deeper understanding of the various business models demonstrated by digital therapeutic companies
  • Up-to-date information on business models of varying successes in the current industry
  • A clear understanding of current routes to market and their intricacies
  • Robust knowledge on how the current commercial landscape impacts your work in this space
  • Your questions answered by industry leaders and your peers
12:00pm

End of Workshop 1

Download Agenda
Workshop 2 - The Regulatory Masterclass

Workshop Leaders: 

Scott Kellogg, Senior Vice President, Regulatory Affairs, Quality Assurance, GMP & Clinical Operations, Akili Interactive

Austin Speier, Chief Strategy Officer, Click Therapeutics

2:00pm

Presentation: An Introduction to DTx Regulation

  • A look at the different levels of regulatory approval available for digital therapeutics
  • Who can the digital therapeutics industry work with to begin and obtain regulatory approval?
  • How can digital therapeutics companies best work with regulators for mutual success?
2:30pm

Breakout Discussions

Splitting into smaller groups, you will discuss the intricacies of the regulatory process for digital therapeutics. Make notes on the virtual platform for all members of the group to contribute to, on the following:

  • What are the different levels of regulatory approval for DTx and how are they defined?
  • How can we best work with the FDA to speed up the regulatory process and ensure both entities are on the same page?
  • How can we learn from others’ successes and failures to ensure we are moving forward as an industry?
  • What impact is the FDA Pre-Cert program having on digital therapeutics?
  • Where should digital therapeutics be focusing clinically for FDA regulatory approval?
3:30pm

Networking Break

4:00pm

Feedback Session

Representative(s) from each group will be invited onto the virtual “stage” to share the main points from their discussion to the whole group. Additional questions from moderators and other group members, via interactive polls, will be raised during this collaborative discussion. 

Summary thoughts will then be shared by the moderator(s) and all participants will leave with the below:

Leave this workshop with:
  • A clear understanding of how digital therapeutics can obtain regulatory approval
  • What claims you can make for each level of regulation
  • An understanding of current FDA clinical trial guidelines in the space
  • What regulators want and need to see from digital therapeutics for successful regulatory approval
  • Your questions answered by industry-leading experts and your peers
5:00pm

End of Workshop 2

Download Agenda

Throughout Main Conference

  • All Day Networking
  • On-Demand Content
All Day Networking

Networking Available All Day

  • 9:00am – 6:00pm: Day 2, Thursday, September 17th

  • 9:00am – 1:00pm: Day 3, Friday, September 18th

As the main agenda progresses throughout the day, you will have the choice of listening in to / participating in the live content or spend more of your time networking with your peers.

Here is how you will be able to achieve this, outside of the networking sessions on the agenda:

  • See who’s in the room – you will be able to message all live attendees and connect with those who respond.
  • Schedule 1-2-1 video calls with your connections at any time that suits you.
  • Open Networking – think of this as the event lobby where you can replicate those all-important “water-cooler” moments.

You will be able to hop seamlessly between networking and on-going agenda sessions at any point.

Download The Agenda
On-Demand Content

On-Demand Content Available All Day

  • 9:00am – 6:00pm: Day 2, Thursday, September 17th

  • 9:00am – 1:00pm: Day 3, Friday, September 18th

DTx East is bursting at the seams with interactive, live content but there are also pre-recorded sessions from more industry-leaders that you can view at your leisure.

These recordings will be available throughout the day, ensuring that you don’t miss any sessions that you want to view or take part in that are happening in real-time.

The Potential of Digital Therapeutics for Treatment in the Real World

  • S-Alpha therapeutics is trying to discover real world area, can be managed by digital therapeutics 
  • An example of development of digital therapeutics which has been discovered according to real world area
  • Insight to reach out to the market with digital therapeutics in the real world

Seung Eun Choi, Chief Executive Officer, S-Alpha Therapeutics

Download the Agenda

Conference Day 2

  • Thursday September 17th
Thursday September 17th
8:00am

Conference Platform Opens

The conference platform opens before the agenda starts, giving you time to plug the presentations, panels and discussions into your agenda for the rest of the day. This also gives you plenty of time to get familiar with the platform.

Location: Stage

9:00am

Chairs Opening Remarks

Matthew Tucker, Executive Director, Strategy & Transformation, Highmark Health

9:05am

Presentation: Innovative Partnerships, Driving Patient Outcomes and Value

  • Why does digital/pharma/device partnerships make sense?
  • Share with the audience vision/mission behind our partnership – Why working together is best for patients
  • What were the opportunities/challenges we faced while scaling this partnership?
  • What does success look like, what are the long term goals for this partnership?

Chris Lento, Head, Healthcare Partnerships, Noom
Jennifer Hartman, Director of Business Development, Life Sciences Partnerships, Noom

9:30am

Wellness Break

Get-up and have a stretch before the next session begins.

9:35am

Panel Discussion & Interactive Q&A: Digital Therapeutics in the Covid-19-Impacted Healthcare System

In just a few months, huge disruption has occurred to healthcare systems across the world as a result of Covid-19. Digital therapeutics are uniquely positioned to deliver for patients with unmet medical needs where more traditional methods may now not be fit for purpose. Hear from industry leaders on how their organizations have adapted to new opportunities. Hear the experts’ thoughts on:

  • How has Covid-19 changed our belief in what digital therapeutics can do for patients?
  • What opportunities have opened up due to the recent changes in healthcare systems?
  • How have payers adapted their thoughts on digital therapeutics in this new age?
  • How can we better work with patients to ensure their new behaviours are factored into our products?
  • What more can we do as an industry to ensure digital therapeutics fill the gaps in healthcare where non-digital methods have previously fallen short?

David Klein, Chief Executive Officer, Click Therapeutics

Liz Kwo, Medical Director, Digital Health, Anthem

Eddie Martucci, Chief Executive Officer, Akili Interactive

Chuck Gammal, Partner, Simon Kucher & Partners

Peter Hames, Chief Executive Officer, Big Health

Location: The Choice is Yours!

10:05am

Optional Break

Catch-up on emails, let the dog out, brew some more coffee… use this time to take care of regular day-to-day life.


 

Location: Sessions

10:05am

Open Q&A with Speakers

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Actively or passively take part in this session.

David Klein, Chief Executive Officer, Click Therapeutics

Liz Kwo, Medical Director, Digital Health, Anthem

Eddie Martucci, Chief Executive Officer, Akili Interactive

Representative from Simon Kucher & Partners

Peter Hames, Chief Executive Officer, Big Health


 

Location: Networking Area

10:25am

Speed Networking

In the purpose-built Networking area, get ready to expand your network through randomly assigned 1 on 1 quick-fire video meetings. You can choose who you want to “connect” with and then set-up 1-2-1 in-depth catch-up’s throughout the rest of the event. 

This function also ensures that you don’t meet the same person more than once, allowing you to meet as many fellow attendees as you desire.

Your future collaborators or partners could be just one click away!

DTx East Virtual will now split into two tracks.

Personalize your experience by hopping in and out of sessions and meetings seamlessly, view on-demand content, or spend time in the Networking area.

Location: Stage

11:05am

Presentation: Determining, demonstrating and communicating the value of digital therapeutics programs using real world data 

  • What are common real world data sources utilized by the life sciences industry today, and how are they used to measure the value of digital therapeutics programs?
  • Review study designs that may be used to demonstrate and communicate digital therapeutic program effectiveness

Rena Meadows, Associate Principal, Real World Solutions, IQVIA

Mitch DeKoven, Senior Principal – Health Economics/Outcomes Research, Real World Insights, IQVIA

 


11:30am

Wellness Break

Get-up and have a stretch before the next session begins.


11:35am

Presentation: The Patient Perspective in Digital Therapeutics

  • What do patients really think of digital therapeutics?
  • An insight into the process of a patient using digital therapeutics over traditional drugs
  • Where can digital therapeutics improve to improve patient engagement, effectiveness and experience?

Burt Rosen, Former President, Society for Participatory Medicine

Jen Horonjeff, Founder & Chief Executive Officer, Savvy Cooperative


12:00pm

Wellness Break

Get-up and have a stretch before the next session begins.


Location – Sessions

12:05pm

Panel Discussion: Going Digital? – Digital Therapeutic Clinical Trials

  • What are the benefits of virtual clinical trials for digital therapeutics over traditional trials?
  • Are the results we’ve seen from virtual clinical trials as good and robust as traditional trials?
  • What do payers think of this new and novel approach for clinical data?
  • What are the drawbacks of virtual clinical trials compared with traditional trials?
  • How do regulators view virtual clinical trials for digital therapeutics?

Malinda Peeples, Senior Vice President, Clinical Services, Programs & Research, Welldoc

Derek Richards, Chief Scientific Officer, SilverCloud Health

Shaheen Lakhan, Head, Clinical / Neurology & Pain Management Consultant, Fern Health / Cambridge Health Alliance

Kate Rosenbluth, Founder & Chief Scientific Officer, Cala Health

Brian Johnson, Director, Applied Innovation, Otsuka Pharmaceuticals


12:35pm-2:00pm

Lunch

Finally, a lunch at a conference that is completely your choice!

Use this extended break to have your regular lunch, spend time with your family and give your brain a break. Recharge for the afternoon session.


Location: Sessions

11:05am

Interactive Roundtable: Unravelling Digital Therapeutics Regulation – What it Means for You

  • A discussion on what evidence is required for FDA approval and what payers and clinicians want to see
  • What has been the impact of the FDA Pre-Cert program on digital therapeutics?
  • Understanding where best to prioritise clinical efforts in relation to regulatory approval

Actively or passively take part in this discussion.

Marisa Cruz, Chief Medical Officer, Limbix

Acacia Parks, Chief Science Officer, Happify Health

Ravi Nunna, Medical Advisor, CureApp


11:45am

Wellness Break

Get-up and have a stretch before the next session begins.


11:50am

Interactive Roundtable:  Pharma-DTx Partnerships

  • What have we learnt from the recent partnership break-ups?
  • How have Pharma’s views on digital therapeutics changed over the last few months?
  • Do digital therapeutics companies need to present their value differently compared to pre-Covid-19?

Actively or passively take part in this discussion.

Melinda Decker, Chief Commercial Officer, Mymee

Amir Lahav, Executive Director, Head of Digital Medicine, Karyopharm Therapeutics


12:25pm

Wellness Break

Get-up and have a stretch before the next session begins.


12:35pm-12:55pm

Open Q&A with Speakers

Actively or passively take part in this discussion.

Malinda Peeples, Senior Vice President, Clinical Services, Programs & Research, Welldoc

Derek Richards, Chief Scientific Officer, SilverCloud Health

Shaheen Lakhan, Vice President, Head of R&D / Neurology & Pain Management Consultant, The Learning Corp / Cambridge Health Alliance

Kate Rosenbluth, Founder & Chief Scientific Officer, Cala Health

Brian Johnson, Director, Applied Innovation, Otsuka Pharmaceuticals


Day 2 of DTx East includes an extended break in the middle to give you ample time for lunch and another chance to catch-up on the day job. Or if you have time, you can use this break for 1-2-1 meetings or open networking.

Location: Expo Area

2:00pm

Tour of Expo

Take a tour of the virtual Expo and interact with partners of DTx East to understand more about their services.

Location: Stage

2:20pm

Presentation: Offering Combined Therapies: Digital Health & Over-The-Counter (OTC) Medicines

  • A case study looking at how 2Morrow partnered with GSK to offer a combined behavioral and pharmaceutical treatment for nicotine addiction
  • Lessons learned from 3 years of real-world experience offering digital behavioral therapy combined with over the counter (OTC) Nicotine Replacement Therapy to address nicotine addiction via employer wellness and population health channels

Jo Masterson, Chief Executive Officer, 2Morrow Inc

James Karl, National Account Manager, GSK


2:45pm

Wellness Break

Get-up and have a stretch before the next session begins.


2:50pm
Presentation: Optimizing Patient Engagement In Digital Therapeutic Trials by Leveraging Digital Solutions and a Virtual Research Team

  • Collaborate with patient representative for software configuration and user testing
  • Assist patients along their treatment journey with patient-centric software and communication tools
  • Closely monitor data in real-time to gain actionable insights into the patient experience

Adam Samson, Director of Clinical Operations, Curebase


3:15pm

Wellness Break

Get-up and have a stretch before the next session begins.


3:20pm
Panel Discussion: Building a Healthcare Ecosystem for Digital Therapeutics Adoption

  • How are clinicians and healthcare providers viewing digital therapeutics?
  • How should digital therapeutic companies work together to build the infrastructure that will get these products to patients?
  • What are the key questions that providers have when digital therapeutic companies approach them?
  • What does the ideal infrastructure for getting digital therapeutics to patients look like?
  • Should digital therapeutic companies be exploring a “digital pharmacy”-type system?

Gregory Dodell, President of Central Park Endocrinology, Assistant Clinical Professor of Endocrinology, Diabetes and Bone Disease, The Mount Sinai Hospital

Patty Scalzo, Director, Diabetes Technology Initiatives, The Association of Diabetes Care & Education Specialists (ADCES)

Audrey Kern, Global Medical Director, Pear Therapeutics

Joe Perekupka, Chief Commercial Officer, Palo Alto Health Sciences


3:50pm

Optional Break

Catch-up on emails, let the dog out, brew some more coffee… use this time to take care of regular day-to-day life.


Location: Sessions

2:20pm

Interactive Roundtable: Digital Therapeutics & Telehealth

  • How has healthcare delivery changed over the past few months?
  • How have the recent changes opened up more opportunities for digital therapeutics?
  • How should digital therapeutics companies work with telehealth providers to get these products into the hands of more patients in need?

Actively or passively take part in this discussion.

John Stamatopoulos, SVP, Payor Strategies, Happify Health


3:00pm

Wellness Break

Get-up and have a stretch before the next session begins.


3:05pm

Interactive Roundtable:  Patient-centric Development for Patient Engagement, Adherence and Clinical Outcomes

  • How can we best design digital therapeutics to keep patients engaged from the start?
  • When do conversations with patients need to start in the development process?
  • How can we marry the worlds of real-world research and product development?

Actively or passively take part in this discussion.

Davina Pallone, Vice President, Product, Fruit Street

Chris Wasden, Head of HappifyDTx, Happify Health

Jessica Lipschitz, Associate Director, Digital Behavioural Health & Informatics Research Program, Brigham & Women’s Hospital

Madhavi Jagdish, Former Director, Product Design, Pear Therapeutics


3:45pm

Wellness Break

Get-up and have a stretch before the next session begins.


3:50pm

Open Q&A with Speakers

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Actively or passively take part in this session.

Gregory Dodell, President of Central Park Endocrinology, Assistant Clinical Professor of Endocrinology, Diabetes and Bone Disease, The Mount Sinai Hospital

Patty Scalzo, Director, Diabetes Technology Initiatives, The Association of Diabetes Care & Education Specialists (ADCES)

Audrey Kern, Global Medical Director, Pear Therapeutics

Joe Perekupka, Chief Commercial Officer, Palo Alto Health Sciences


Location: Stage

4:10pm

Wellness Break

Get-up and have a stretch before the next session begins.

4:15pm

Presentation: Using Real-World Data to Decode “What Works” in Digital Care Delivery

Andy Blackwell, Chief Scientific Officer, Ieso Digital Health

4:40pm

Wellness Break

Get-up and have a stretch before the next session begins.

4:45pm

Presentation: Specialty Pharmacy? Why do I Need One for my Prescription DTx?

  • What is a specialty pharmacy, what is a hub, and why is it needed?
  • How would the mechanics of a specialty pharmacy work in DTx vs for a drug?
  • How can I utilize a specialty pharmacy for my prescription DTx?

Ed Cox, Executive Vice President, Strategic Alliances & Global Head of Digital Medicine, EVERSANA

Tom Doyle, Sr Vice President, Global Strategic Accounts, EVERSANA

Brian Davis, Vice President Strategy and Innovation, EVERSANA

5:10pm

Wellness Break

Get-up and have a stretch before the next session begins.

5:15pm

Panel Discussion & Interactive Q&A: What is the True Value of Digital Therapeutics?

  • Where does the true “value” of digital therapeutics lie?
  • How does this value change based on the new Covid-19-impacted healthcare systems we find ourselves in?
  • With a huge increase in the demote for remote digital care, how does this impact the value of digital therapeutics?
  • Does this open up new reimbursement opportunities outside of the ones we have been previously exploring?
  • Will DTx/Drug combination therapies open up more commercialization and reimbursement opportunities for the industry?

Jonas Thinggaard, Head of Technology Scouting and Incubation, Digital Therapeutics, Novo Nordisk

Ofer Leidner, Co-Founder & President, Happify Health

Alex Waldron, Chief Strategy Officer, Pear Therapeutics

Megan Coder, Executive Director, Digital Therapeutics Alliance

Location: Sessions

5:45pm – 7:30pm

Virtual Drinks

Share a virtual drink with old friends or new connections. At small virtual tables, this is your chance to casually interact with the rest of the Digital Therapeutics industry.


 

Location: Sessions

5:45pm – 6:05pm

Open Q&A with Speakers

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Actively or passively take part in this session.

Jonas Thinggaard, Head of Technology Scouting and Incubation, Digital Therapeutics, Novo Nordisk

Ofer Leidner, Co-Founder & President, Happify Health

Alex Waldron, Chief Strategy Officer, Pear Therapeutics

Megan Coder, Executive Director, Digital Therapeutics Alliance


 

Download Agenda

Conference Day 3

  • Friday September 18th
Friday September 18th
8:00am

Conference Platform Opens

The conference platform opens an hour before the sessions begin so that you can plug the presentations, panels and discussions into your calendar for the day ahead.

Location: Stage

9:00am

Chairs Opening Remarks

Sarah Jackson, Chief of Staff, Click Therapeutics

9:05am

Panel Discussion: How Should Digital Therapeutics be Impacting the Lives of Patients?

 Digital therapeutics have a huge opportunity to deliver for patients with unmet medical needs in a wide range of health conditions, particularly in the Covid-19-impacted healthcare systems we find ourselves in. However, crucial questions must be asked to ensure that these products truly deliver for patients. Hear the experts’ thoughts on: 

  • As we stand today, what are digital therapeutics doing for patients?
  • In what areas can digital go above and beyond traditional therapeutics?
  • What is going to stop digital therapeutics from reaching their full potential?
  • What areas of success in the wider digital health landscape can we learn from when attempting to demonstrate the value of digital therapeutics?
  • How can we work closer with patients to ensure further adoption of digital therapeutics?

Joanna Mitri, Staff Physician / Instructor in Medicine, Joslin Diabetes Center / Harvard Medical School

Anand Iyer, Chief Strategy Officer, Welldoc

Ted James, Chief, Breast Surgical Oncology & Director, Breast Care Center, Beth Israel Deaconess Medical Center

Mae-ellen Gavin, Senior Vice President, Product, Akili Interactive

Rochelle Porper, Vice President, Business Development, Palo Alto Health Sciences

Lindsey Miller, Development Associate, The Accelerated Cure Project for MS

Location: The Choice is Yours!

9:35am

Optional Break

Catch-up on emails, let the dog out, brew some more coffee… use this time to take care of regular day-to-day life.


 

Location: Sessions

9:35am

Open Q&A with Speakers

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Actively or passively take part in this session.

Joanna Mitri, Staff Physician / Instructor in Medicine, Joslin Diabetes Center / Harvard Medical School

Anand Iyer, Chief Strategy Officer, Welldoc

Ted James, Chief, Breast Surgical Oncology & Director, Breast Care Center, Beth Israel Deaconess Medical Center

Mae-ellen Gavin, Senior Vice President, Product, Akili Interactive

Rochelle Porper, Vice President, Business Development, Palo Alto Health Sciences

Lindsey Miller, Development Associate, The Accelerated Cure Project for MS


 

Location: Stage

9:55am

Wellness Break

Get-up and have a stretch before the next session begins.

10:00am

Panel Discussion & Interactive Q&A: What do Pharma Really Think of Digital Therapeutics?

Answering the age-old question to truly identify what pharma thinks of digital therapeutics. In recent months, there has been a smattering of both partnerships and breakups between pharma and DTx companies. This panel, stacked with pharma leaders, will deep-dive into the pharmaceutical perspective of digital therapeutics. Hear the experts’ thoughts on:

  • From a pharma perspective, what is the true value of digital therapeutics?
  • How has the impact of Covid-19 changed your view on the potential of digital therapeutics?
  • What have we learned from both the more and less successful pharma partnerships?
  • Does there need to be a new approach taken to ensure successful partnerships in the future?
  • How can both DTx companies and pharma companies ensure successful and mutually beneficial partnerships?

Michael Latauska, Director, Digital Health, Boehringer Ingelheim

Lauren Li, Head of Digital Health, Ipsen

Joris van Dam, Executive Director, Head of Digital Therapeutics, Novartis

Paul Upham, Head, Smart Devices, Roche / Genentech

Rachel Sha, Vice President, Digital Business Development, Sanofi

Location: Networking Area

10:30am

Speed Networking

Through the purpose built Networking on function, get ready to expand your network through randomly assigned 1 on 1 quick fire interactions. You can choose who you want to “connect” and then set-up 1-2-1 in-depth meetings throughout the rest of the event.

This function also ensures that you don’t meet the same person more than once, allowing you to meet as many fellow attendees as you desire.

Your future collaborators or partners could be just one click away!


Location: Sessions

10:30am – 10:50am

Open Q&A with Speakers

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Actively or passively take part in this session.

Michael Latauska, Director, Digital Health, Boehringer Ingelheim

Lauren Li, Head of Digital Health, Ipsen

Joris van Dam, Executive Director, Head of Digital Therapeutics, Novartis

Paul Upham, Head, Smart Devices, Roche / Genentech

Rachel Sha, Vice President, Digital Business Development, Sanofi


10:50am

Optional Break

Catch-up on emails, let the dog out, brew some more coffee… use this time to take care of regular day-to-day life.

Location: Stage

11:15am

Presentation: An Insight into European Digital Therapeutics Regulation and an Update on the new German Legislation

  • A deep-dive into the process of obtaining DTx reimbursement through the new German legislation
  • How has this changed DTx reimbursement opportunities in Germany?
  • How are GAIA’s digital therapeutics moving through this new reimbursement pathway?

Matthias Zenker, Partner, GAIA AG


11:30am

Wellness Break


11:35am

Presentation: Improving Behavioral Health through Virtual Reality Digital Therapeutics

  • Why VR is such an appealing medium for behavioral health interventions
  • How COVID-19 has accelerated the coupling of digital therapeutics and telehealth
  • A look at BehaVR’s products, pipeline and results so far

Aaron Gani, Founder & Chief Executive Officer, BehaVR


11:50am

Wellness Break


11:55am

Presentation: Becoming a Virtual Sleep Disorder Provider

  • How is Dreem enabling access to sleep in a similar way to a healthcare provider
  • Showcase of real world evidence on Dreem’s insomnia therapy studies
  • Discussion will focus on the personalization of digital therapeutics

Vik Panda, Managing Director, North America, Dreem


Location: Sessions

11:15am

Interactive Open Mic Session

This open mic session will enable you to suggest the topics you would like to hear more about.

If there was a topic that was covered in the agenda but you wish to go deeper, or a new topic that wasn’t showcased, this is your chance to discuss with peers. The choice is yours!

Facilitators will initiate the discussion and ensure that topics are stuck to and will cultivate guidance and answers to your questions.

Actively or passively take part in this discussion.

Owen McCarthy, Co-Founder & President, MedRhythms

Andy Molnar, Vice President, Market Access, Cognoa


Location: Stage

12:10pm

Wellness Break

Get-up and have a stretch before the next session begins.

12:15pm

Panel Discussion: A Minds Eye View of Digital Therapeutics – An Investor Perspective

As the digital therapeutics enters the next phase in its lifecycle, the sentiment from the investor community is changing. Tap into the mind of leading investors to understand how digital therapeutic companies and their partners should alter their approaches. Hear the experts’ thoughts on:

  • What are investors looking for from digital therapeutic companies to prompt them to pull the trigger on investment?
  • How has Covid-19 impacted our assessment of the investment opportunities in digital therapeutics?
  • How can DTx companies prepare to secure multiple rounds of funding from the start?
  • Where do investors think the risk lies in investing in digital therapeutics?
  • How can DTx best source the right investment partner to ensure future success?

Chihiro Hosoya, Head of Venture Management & Business Development, Rx+ Business Accelerator, Astellas Pharma

Debbie Lin, Executive Director, Boehringer Ingelheim Venture Fund

Zack Lynch, Managing Partner, JAZZ Venture Partners 

Caleb Winder, Managing Director, MemorialCare Innovation Fund

Brent Vaughan, Healthcare Venture Capital, Morningside Ventures

Location: Sessions

12:45pm

Open Q&A with Speakers

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Actively or passively take part in this session.

Chihiro Hosoya, Head of Venture Management & Business Development, Rx+ Business Accelerator, Astellas Pharma

Debbie Lin, Executive Director, Boehringer Ingelheim Venture Fund

Zack Lynch, Managing Partner, JAZZ Venture Partners 

Caleb Winder, Managing Director, MemorialCare Innovation Fund

Brent Vaughan, Healthcare Venture Capital, Morningside Ventures

1:05pm

Close of DTx East 2020

Roll straight into your weekend, with no flight to catch!

Download Agenda